Pittenger & Anderson Inc. Sells 1,574 Shares of Medpace Holdings, Inc. $MEDP

Pittenger & Anderson Inc. trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 88.6% during the first quarter, HoldingsChannel reports. The fund owned 202 shares of the company’s stock after selling 1,574 shares during the period. Pittenger & Anderson Inc.’s holdings in Medpace were worth $97,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. NewEdge Advisors LLC increased its holdings in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of Medpace during the second quarter worth about $296,000. Finally, M&T Bank Corp boosted its position in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after buying an additional 31 shares during the period. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

MEDP has been the topic of a number of recent research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Barclays decreased their price target on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. BMO Capital Markets lowered their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $547.00 price objective (up from $477.00) on shares of Medpace in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $469.17.

Insider Buying and Selling at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 20.50% of the stock is owned by company insiders.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $538.23 on Monday. The business has a 50-day moving average of $467.24 and a 200-day moving average of $495.50. The stock has a market capitalization of $15.37 billion, a price-to-earnings ratio of 33.83, a PEG ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same quarter in the prior year, the company posted $3.67 earnings per share. Medpace’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.